Histopathological evaluation and immunohistochemical study of Histopathological evaluation and immunohistochemical study of estrogen receptor α, HER-2 and Ki-67 in canine neoplastic mammary estrogen receptor α, HER-2 and Ki-67 in canine neoplastic mammary lesions lesions

The frequency of different types of mammary lesions and their relationship with histologic grade was investigated. One hundred and forty-six mammary lesions were classifi ed according to the World Health Organization (WHO) criteria. Selected lesions (51 malignant and 24 benign) were investigated to determine the immunohistochemical expression of estrogen receptor alpha (ERα), HER-2 and Ki-67 and their relationship with tumor factors. The most common breeds affected were cross breeds, poodles, cocker spaniels and German shepherds and the median age of tumor diagnosis was 10 years (range 4 - 15 years of age). Classifi cation of all canine mammary gland lesions revealed 110 (75.3%) malignant and 36 (24.7%) benign tumors. ERα was expressed by 9/24 (37.5%) benign and 9/51 (17.6%) malignant tumors. HER-2 protein was detected in 5/51 (9.8%) malignant tumors but none in the 24 benign tumors. The Ki-67 index was higher in malignant (mean 29.5) than benign (mean 9.1) tumors (P<0.001) and signifi cantly higher in anaplastic carcinomas than tubulopapillary carcinomas (P<0.05).

[1]  F. Schmitt,et al.  The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours. , 2009, Veterinary and comparative oncology.

[2]  W. Hsu,et al.  Increased survival in dogs with malignant mammary tumours overexpressing HER-2 protein and detection of a silent single nucleotide polymorphism in the canine HER-2 gene. , 2009, Veterinary journal.

[3]  Joanna S Morris,et al.  Expression of TopBP1 in canine mammary neoplasia in relation to histological type, Ki67, ERalpha and p53. , 2009, Veterinary journal.

[4]  F. Schmitt,et al.  Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification , 2008, Virchows Archiv.

[5]  M. L. Dagli,et al.  The search for suitable prognostic markers for canine mammary tumors: A promising outlook. , 2008 .

[6]  W. Misdorp,et al.  Tumors of the Mammary Gland , 2008 .

[7]  J. Thuróczy,et al.  Immunohistochemical detection of progesterone and cellular proliferation in canine mammary tumours. , 2007, Journal of comparative pathology.

[8]  Marta Susana Amaro Dos Santos,et al.  MIB-1 labelling indices according to clinico-pathological variables in canine mammary tumours: a multivariate study. , 2006, Anticancer research.

[9]  F. Schmitt,et al.  Selecting Antibodies to Detect HER2 Overexpression by Immunohistochemistry in Invasive Mammary Carcinomas , 2006, Applied immunohistochemistry & molecular morphology : AIMM.

[10]  F. Millanta,et al.  Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues. , 2005, Research in veterinary science.

[11]  A. Killeen.  Principles of Molecular Pathology , 2003 .

[12]  S. Ramón y. Cajal,et al.  Oncogene HER-2 in Canine Mammary Gland Carcinomas , 2003, Breast Cancer Research and Treatment.

[13]  G. Castellani,et al.  Prognostic Value of Histologic Stage and Proliferative Activity in Canine Malignant Mammary Tumors , 2002, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

[14]  G. Lazzeri,et al.  MIB-1 Labeling Index in Feline Dysplastic and Neoplastic Mammary Lesions and Its Relationship with Postsurgical Prognosis , 2002, Veterinary pathology.

[15]  L. Peña,et al.  Immunohistologic Detection of Estrogen Receptor Alpha in Canine Mammary Tumors: Clinical and Pathologic Associations and Prognostic Significance , 2000, Veterinary pathology.

[16]  F. Shofer,et al.  Effect of spaying and timing of spaying on survival of dogs with mammary carcinoma , 2000 .

[17]  H. Takahashi,et al.  p53 Gene Mutations Occurring in Spontaneous Benign and Malignant Mammary Tumors of the Dog , 2000, Veterinary pathology.

[18]  F. Schmitt,et al.  Immunohistochemical study of hormonal receptors and cell proliferation in normal canine mammary glands and spontaneous mammary tumours , 2000, Veterinary Record.

[19]  J. Fletcher,et al.  The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. , 1999, Seminars in cancer biology.

[20]  Toshiharu Hayashi,et al.  Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. , 1999, The Journal of veterinary medical science.

[21]  P. Cuesta,et al.  Immunohistochemical Detection of Ki-67 and PCNA in Canine Mammary Tumors: Relationship to Clinical and Pathologic Variables , 1998, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

[22]  R. C. Bird,et al.  Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines. , 1996, American journal of veterinary research.

[23]  C. Cornelisse,et al.  DNA flow cytometry of canine mammary tumours: the relationship of DNA ploidy and S-phase fraction to clinical and histological features. , 1995, Research in veterinary science.

[24]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.

[25]  C.T. Lin,et al.  Proliferative activity, apoptosis and expression of oestrogen receptor and Bcl-2 oncoprotein in canine mammary gland tumours. , 2006, Journal of comparative pathology.

[26]  A. Nečas,et al.  Breed and Age as Risk Factors for Canine Mammary Tumours , 2005 .